Bioengineered cell therapies for pediatric solid tumors: unmet needs and a measurement-integrated approach
Progress in Biomedical Engineering · 2026
DOI: 10.1088/2516-1091/aea045 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Progress in Biomedical Engineering, 2026. Verfasst von Ana M Sandoval-Castellanos und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Engineering, University of California Davis, Davis, CA 95616, United States of America. Hauptthemen laut MEDLINE: Neoplasms, Bioengineering, Cell- and Tissue-Based Therapy. Die Arbeit nennt 76 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, National Cancer Institute, Hartwell Foundation.
Abstract (Originalsprache)
Pediatric solid tumors continue to pose a major therapeutic challenge, with survival gains lagging behind those achieved in pediatric hematologic malignancies. While traditional approaches have focused on dose escalation and intensification of systemic therapies to improve survival, this strategy is often limited by significant short- and long-term morbidity from intensive multimodal treatment. Because children have developing organs and decades of life ahead, therapeutic strategies must balance durable tumor control with preservation of neurodevelopment, organ function, and quality of life. Immunotherapy has generated significant interest as an alternative to dose escalation; however, clinical translation in pediatric solid tumors has been limited by antigen heterogeneity, tumor plasticity, immune-cold or immune-excluded phenotypes, and a profoundly immunosuppressive tumor microenvironment. Bioengineered cellular therapies, particularly chimeric antigen receptor (CAR) T cells and CAR-modified natural killer (CAR NK) cells, provide a modular platform to address these barriers through synthetic receptor design, multi-antigen targeting, controlled activation, and improved trafficking to anatomically restricted sites such as the brain. However, engineering advances alone are unlikely to achieve durable benefit without parallel integration of quantitative in vivo monitoring capable of reporting biodistribution, persistence, and functional engagement. Non-invasive imaging and measurement-enabled approaches can provide mechanistic insight into therapeutic performance, discriminate between delivery failure and functional dysfunction, and support rational iteration of construct design, dosing, and route of administration. In this perspective, we review the current status of CAR T and CAR NK therapies in pediatric solid malignancies, outline key biological and engineering challenges, and propose a pediatric-centered development framework that integrates controllable cell engineering with quantitative, non-invasive assessment of in vivo behavior. By embedding measurement into the therapeutic design loop and prioritizing long-term safety and developmental outcomes alongside efficacy, next-generation engineered cell therapies may evolve toward adaptable, precision-guided systems capable of improving both survival and quality of life for children.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biomedical Engineering, University of California Davis, Davis, CA 95616, United States of America.
- Department of Surgery, School of Medicine, University of California Davis, Sacramento, CA 95817, United States of America.
- Department of Ophthalmology and Vision Science, University of California Davis, Sacramento, CA 95817, United States of America.
- Center for Bioengineering in Medicine, School of Medicine, University of California Davis, Sacramento, CA 95817, United States of America.
ORCID-Profile: Robert J Canter, Erin G Brown, Jinhwan Kim
Förderung
- NCI NIH HHS
- National Cancer Institute
- Hartwell Foundation
Zitieren
APA
Sandoval-Castellanos, A. M., Ahn, Y. R., Canter, R. J., Brown, E. G., & Kim, J. (2026). Bioengineered cell therapies for pediatric solid tumors: unmet needs and a measurement-integrated approach. Progress in Biomedical Engineering. https://doi.org/10.1088/2516-1091/aea045
Vancouver
Sandoval-Castellanos AM, Ahn YR, Canter RJ, Brown EG, Kim J. Bioengineered cell therapies for pediatric solid tumors: unmet needs and a measurement-integrated approach. Progress in Biomedical Engineering. 2026. doi:10.1088/2516-1091/aea045
BibTeX
@article{SandovalCastellanos2026,
author = {Sandoval-Castellanos, Ana M and Ahn, Yu-Rim and Canter, Robert J and Brown, Erin G and Kim, Jinhwan},
title = {Bioengineered cell therapies for pediatric solid tumors: unmet needs and a measurement-integrated approach},
journal = {Progress in Biomedical Engineering},
year = {2026},
doi = {10.1088/2516-1091/aea045}
}
EUVIMED